Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Dimethoxybenzene SCHEMBL5960077 | 0.90 | CA1 (0.65) | PKMCA1CA2CA9CA12 | |
| SCHEMBL4617270 | 0.88 | HPGD (0.59) | HPGDNFE2L2PKMCA1CA2 | |
| SCHEMBL154527 | 0.87 | — | — | |
| SCHEMBL2226770 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL11293911 | 0.85 | CA1 (0.65) | HPGDNFE2L2CA1CA2CA9 | |
| Chloromethane SCHEMBL9703019 | 0.85 | CA1 (0.65) | HPGDNFE2L2CA1CA2CA9 | |
| Iodide SCHEMBL5695908 | 0.85 | CA1 (0.65) | HPGDNFE2L2CA1CA2CA9 | |
| Water SCHEMBL9443323 | 0.85 | CA1 (0.65) | HPGDNFE2L2CA1CA2CA9 | |
| SCHEMBL4444134 | 0.85 | CA1 (0.65) | HPGDNFE2L2CA1CA2CA9 | |
| SCHEMBL28525728 | 0.85 | CA1 (0.65) | HPGDNFE2L2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448581-B1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2016-12-07 | — | — | EP | disclosed |
| CN-103012407-B | N-[4-(1H-pyrazolo [3,4-b] pyrazine-6-base)-phenyl]-sulfonamides and the purposes as medicine thereof | 赛诺菲 | 2016-06-29 | — | — | CN | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| CN-102413693-B | Nematocidal sulfonamides | DU PONT | 2014-01-15 | — | — | CN | disclosed |
| CN-103012407-A | N-[4-(1H-pyrazolo[3,4-b]pyrazine-6-yl)-phenyl]-sulfonamides and application of N-[4-(1H-pyrazolo[3,4-b]pyrazine-6-yl)-phenyl]-sulfonamides as medicines | SAI NUOFEI | 2013-04-03 | — | — | CN | disclosed |
| CN-101378757-B | Thiadiazole derivatives for the treatment of neuro degenerative diseases | REMYND NV | 2012-08-01 | — | — | CN | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| EP-2448581-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002816-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1583533-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1438298-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | Pfizer Products Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040092529-A1 | Methods of using piperazine derivatives | PFIZER INC | 2004-05-13 | — | — | US | disclosed |
| WO-2004039376-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2003035627-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| CN-1037568-C | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1998-03-04 | — | — | CN | disclosed |
| CN-1165143-A | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-11-19 | — | — | CN | disclosed |
| CN-1165144-A | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-11-19 | — | — | CN | disclosed |
| CN-1066266-A | PHOSPHOSULFONATE HERBICIDES | ROHM & HAAS (US) | 1992-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092529-A1 | Methods of using piperazine derivatives | CCR1, CCR3, CCR5 | HPGD 1457/4885NFE2L2 2187/4885PKM 3596/4885 |
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | HPGD 2160/4885NFE2L2 2113/4885PKM 3617/4885 |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | HPGD 934/4885NFE2L2 1106/4885PKM 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.